Compared with low-dose aspirin, there was a trend toward an improvement in graft patency in favor of medium- statistical significance was not achieved, the authors advo- cated for the use of aspirin at a medium dose of 325 mg daily because of its excellent safety profile and minimal increase in cost. This finding is in agreement with the results of previous studies that demonstrated that lower doses of aspirin (100 200 mg) may be insufficient to effectively inhibit platelet function early after CABG as a result of resistance to the antiplatelet effect of aspirin in the postoperative period.23,24 A phenom- enon called aspirin resistance, this factor may adversely affect postoperative vein graft patency.23,25,26 Receptor Inhibitors Clopidogrel is a thienopyridine antiplatelet agent that irre- versibly inhibits the platelet P2Y12 adenosine diphosphate receptor. When exposed to clopidogrel, platelets are inhib- ited from aggregating for the remainder of their 7- to 10-day In contrast to ticlopidine, a thienopyridine that had been shown to improve graft patency,29,30 clopidogrel is 7-fold more potent and free of the unfavorable side effect profile of ticlopidine, which includes neutropenia and rash.28 Combining aspirin therapy with clopidogrel leads to potent synergistic antithrombotic effects,31 and substantial benefits have been demonstrated in several CAD trials studying the impact of dual antiplatelet therapy.32,33 The potential clinical benefits of clopidogrel administra- tion after CABG were first evaluated in subgroup analyses from the Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events (CURE) and Clopidogrel for the Reduction of Events During Observation (CREDO) multicenter trials. In the CURE study, 12562 patients presenting with acute coro- nary syndromes without ST-segment elevation were random- ized to aspirin alone or aspirin plus clopidogrel for 3 to 12 months. 